• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting

February 26 - March 1, 2021

  1. Benralizumab
  2. Tezepelumab
  3. US PRECISION
  4. CHRONICLE

Html

The Effect of Benralizumab On Allergen-Induced Responses In Subjects With Mild Allergic Asthma [Abstract 500]

Pdf

Elimination of Oral Corticosteroids (OCS) with Benralizumab Treatment in OCS-Dependent Asthmatics Using a Rapid, Personalized Algorithm:The PONENTE Trial

Html

Biologic Pathways Involved in Chronic Spontaneous Urticaria and Response to Benralizumab Treatment [Abstract 501]

Pdf

Clinical and Economic Burden of Patients with Uncontrolled Severe Asthma with Low Blood Eosinophil Levels in the United States

Pdf

Efficacy And Safety Of Tezepelumab In Adults And Adolescents With Severe, Uncontrolled Asthma:Results From The Phase 3 NAVIGATOR Study

Pdf

Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY phase 2b study

Html

Treatment with Tezepelumab Reduces Serum Interleukin (IL)-5 and IL-13 in Patients with Severe, Uncontrolled Asthma to Levels Approaching those Observed in Healthy Individuals

Html

Baseline Asthma Impairment and Risk Questionnaire (AIRQ™) Control Level is Associated with Future Risk of Exacerbations [Abstract 148]

Html

Which Severe Asthma Patients Are Switching, Stopping, or Continuing Biologic Treatments? [Abstract 178]

Html

Effects of Sex and Age on Characteristics of US Patients with Severe Asthma [Abstract 147]

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice